Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

NCOA4 (Nuclear Receptor Coactivator 4)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation	Marginal Zone Lymphoma	NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation	Marginal Zone Lymphoma	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4
NCOA4-RET fusion	Thyroid Gland Papillary Carcinoma	NCOA4-RET fusion	Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: C4 – Case Studies lenvatinib Sensitive : C4	lenvatinib Sensitive: C4 – Case Studies lenvatinib Sensitive : C4
NCOA4-RET fusion	Thyroid Gland Carcinoma	NCOA4-RET fusion	Thyroid Gland Carcinoma	pralsetinib Sensitive: C4 – Case Studies pralsetinib Sensitive : C4	pralsetinib Sensitive: C4 – Case Studies pralsetinib Sensitive : C4
NCOA4-RET fusion	Cholangiocarcinoma	NCOA4-RET fusion	Cholangiocarcinoma	pralsetinib Sensitive: C4 – Case Studies pralsetinib Sensitive : C4	pralsetinib Sensitive: C4 – Case Studies pralsetinib Sensitive : C4
NCOA4-RET fusion	Thyroid Gland Papillary Carcinoma	NCOA4-RET fusion	Thyroid Gland Papillary Carcinoma	selpercatinib Sensitive: C4 – Case Studies selpercatinib Sensitive : C4	selpercatinib Sensitive: C4 – Case Studies selpercatinib Sensitive : C4
NCOA4-RET fusion	Non Small Cell Lung Cancer	NCOA4-RET fusion	Non Small Cell Lung Cancer	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D
NCOA4-RET fusion	Ovarian Cancer	NCOA4-RET fusion	Ovarian Cancer	FHND5071 Sensitive: D – Preclinical FHND5071 Sensitive : D	FHND5071 Sensitive: D – Preclinical FHND5071 Sensitive : D